RxDoctor Payments Data

Louise Linke

Gerontology · Rochester, NYNPI 1417291410

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 62.2% of it on its own, with 12 other manufacturers making up the rest.

$957in general payments, 2019–2025

Across 80 payments — averaging $11.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$595
  • AbbVie$102
  • Braintree Laboratories, Inc.$47
  • Regeneron Healthcare Solutions, Inc.$44
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • Ardelyx, Inc.$23
  • plus $116 from 7 others

What the payments were for

  • Food & beverage$957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$957 in reported general payments places this provider in the 80th percentile of 187 gerontology providers in New York.

See all gerontology providers in New York

Medicare billing

Part B allowed, 2024
$29,455
Medicare patients
234
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide111$81,893
Humira(Cf) PenAdalimumab12$77,753
TrulancePlecanatide62$39,400
Mesalamine56$30,928
CreonLipase/Protease/Amylase14$29,946
SutabSod Sulf/Pot Chloride/Mag Sulf175$27,595
ErythromycinErythromycin Base75$18,918
Famotidine562$12,140
Ursodiol47$9,107
Dexlansoprazole DrDexlansoprazole22$7,943
Colesevelam Hcl80$7,867
Sucralfate67$7,360
Lubiprostone41$5,953
Pantoprazole Sodium512$5,282
Mesalamine ErMesalamine25$4,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$102$111,839125 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$595$39,40062 claims
Braintree Laboratories, Inc.Sutab$47$27,595175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 gerontology providers in New York.

Other gerontology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →